מדינה: ארצות הברית
שפה: אנגלית
מקור: NLM (National Library of Medicine)
ONDANSETRON HYDROCHLORIDE (UNII: NMH84OZK2B) (ONDANSETRON - UNII:4AF302ESOS)
GlaxoSmithKline LLC
ONDANSETRON HYDROCHLORIDE
ONDANSETRON 4 mg in 5 mL
ORAL
PRESCRIPTION DRUG
ZOFRAN® is indicated for the prevention of nausea and vomiting associated with: ZOFRAN is also indicated for the prevention of postoperative nausea and/or vomiting. ZOFRAN is contraindicated in patients: Risk Summary Available data do not reliably inform the association of ZOFRAN and adverse fetal outcomes. Published epidemiological studies on the association between ondansetron and fetal outcomes have reported inconsistent findings and have important methodological limitations hindering interpretation [see Data ]. Reproductive studies in rats and rabbits did not show evidence of harm to the fetus when ondansetron was administered during organogenesis at approximately 6 and 24 times the maximum recommended human oral dose of 24 mg/day, based on body surface area, respectively [see Data ]. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the US general population, the estimated background risk of major birth defects and miscarriages in clinically recognize
ZOFRAN Tablets ZOFRAN ODT Orally Disintegrating Tablets ZOFRAN Oral Solution Store upright between 15°C and 30°C (59°F and 86°F). Protect from light. Store bottles upright in cartons.
New Drug Application
ZOFRAN- ONDANSETRON HYDROCHLORIDE SOLUTION ZOFRAN ODT- ONDANSETRON HYDROCHLORIDE TABLET, ORALLY DISINTEGRATING ZOFRAN- ONDANSETRON HYDROCHLORIDE TABLET, FILM COATED GLAXOSMITHKLINE LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ZOFRAN TABLETS, ZOFRAN ODT, AND ZOFRAN ORAL SOLUTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ZOFRAN TABLETS, ZOFRAN ODT, AND ZOFRAN ORAL SOLUTION. ZOFRAN (ONDANSETRON HYDROCHLORIDE) TABLETS, FOR ORAL USE ZOFRAN ODT (ONDANSETRON) ORALLY DISINTEGRATING TABLETS ZOFRAN (ONDANSETRON HYDROCHLORIDE) ORAL SOLUTION INITIAL U.S. APPROVAL: 1991 INDICATIONS AND USAGE ZOFRAN is a 5-HT receptor antagonist indicated for the prevention of: • • • • DOSAGE AND ADMINISTRATION • • DOSAGE FORMS AND STRENGTHS • • • CONTRAINDICATIONS • • WARNINGS AND PRECAUTIONS • • • • • 3 nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m . (1) 2 nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. (1) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. (1) postoperative nausea and/or vomiting. (1) See full prescribing information for the recommended dosage in adults and pediatrics. (2) Patients with severe hepatic impairment: do not exceed a total daily dose of 8 mg. (2.2, 8.6) Tablets: 4 mg and 8 mg (3) Orally Disintegrating Tablets: 4 mg and 8 mg (3) Oral Solution: 4 mg/5 mL (3) Patients known to have hypersensitivity (e.g., anaphylaxis) to ondansetron or any components of the formulation. (4) Concomitant use of apomorphine. (4) Hypersensitivity reactions including anaphylaxis and bronchospasm: Discontinue ZOFRAN if suspected. Monitor and treat promptly per standard of care until signs and symptoms resolve. (5.1) QT interval prolongation and Tors קרא את המסמך השלם